JAZZ Jazz Pharmaceuticals plc — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$254.22

Period return

+83.22 (+48.67%)

Volume

786.4K

2026-07-21O $244.65 H $255.2 L $242.11 C $254.22MA5 $245.34MA20 $240.43MA60 $230.9MA120 $206.69

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 14 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 28.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 05. 22.MediumHOLD2 months ago
Bernstein: Market Perform
US analyst rating / recommendation change.
2026. 05. 22.LowBUY2 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 05. 20.MediumBUY2 months ago
UBS: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.12%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 07.LowBUY3 months ago
TD Cowen: Buy
US analyst rating / recommendation change.
2026. 05. 07.LowBUY3 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 05. 07.LowBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $253.21 · 19 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	$6.18	—	—	$1.11B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-1.52	—	—	$897.8M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$5.63	—	—	$2.98B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$2.35	—	—	$1.93B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	358,634	$67.8M	0.12%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	175,000	$29.75M	0.05%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	19,600	$3.71M	0.00%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,400	$408K	0.00%	—	New position

Jazz Pharmaceuticals plc

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 28.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 05. 22.	Bernstein	—	Initiate coverage	— → Market Perform	—	Bernstein: Market Perform
2026. 05. 22.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 05. 20.	UBS	—	Upgrade	Neutral → Buy	—	UBS: Neutral → Buy
2026. 05. 07.	TD Cowen	—	Maintain	Buy → Buy	—	TD Cowen: Buy
2026. 05. 07.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform